ORYZON Announces Voting Results from its 2023 Annual General Meeting of Shareholders

2 years ago

All resolutions were approved.35% of the issued shares represented.MADRID, Spain and BOSTON, June 27, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics,…

BetterLife Fast Tracks Its US Patent for BETR-001 and Other LSD Derivatives

2 years ago

VANCOUVER, British Columbia, June 27, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF…

Immutep Secures Third United States Patent for Eftilagimod Alpha in Combination with a PD-1 Pathway Inhibitor

2 years ago

Media Release SYDNEY, AUSTRALIA, June 27, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company…

Assure Holdings Expands Service Offerings to Address the High Growth EEG Services Market

2 years ago

Signs Diagnostics Services Agreement with Neurovative DiagnosticsDENVER, June 27, 2023 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”)…

Immutep Completes A$80 Million Capital Raise

2 years ago

Media Release SYDNEY, AUSTRALIA, June 27, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”),…

Microbot Medical Announces $2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

2 years ago

HINGHAM, Mass., June 27, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into…

Journal of Clinical Oncology Publishes Results of Corcept’s Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer

2 years ago

Relacorilant plus nab-paclitaxel improved progression-free survival (PFS), duration of response (DoR) and overall survival (OS), without increasing side effects, compared…

Emergent BioSolutions Announces CEO Transition

2 years ago

Robert G. Kramer Sr. to Retire Haywood Miller to Serve as Interim CEO GAITHERSBURG, Md., June 27, 2023 (GLOBE NEWSWIRE)…

Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed/Refractory Multiple Myeloma

2 years ago

SOUTH SAN FRANCISCO, Calif., June 27, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing…